Gene Therapy Start-Up Voyager Therapeutics Impresses with US$845 M Genzyme Deal
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 3 (Table of Contents)
Published: 6 Mar-2015
DOI: 10.3833/pdr.v2015.i3.2095 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Genzyme, a long-time investor in the gene therapy field, has committed to pay Voyager Therapeutics US$100 M upfront to collaborate on the development and commercialisation of the start-up’s pipeline of adeno-associated virus (AAV)-based gene therapies for severe CNS disorders, including Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS